Clinical Trials Logo

Clinical Trial Summary

This study is enrolling participants by invitation only. This is an open-label, safety extension study for subjects who participated in the ARC007 study.


Clinical Trial Description

This is a Phase 3, multi-center, North American, open-label, long-term, safety extension study for eligible subjects who received AR101 therapy in the ARC007 trial (NCT03126227) and completed the study. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03337542
Study type Interventional
Source Aimmune Therapeutics, Inc.
Contact
Status Completed
Phase Phase 3
Start date October 18, 2017
Completion date September 20, 2019

See also
  Status Clinical Trial Phase
Recruiting NCT05667610 - Immune-supportive Diet and Gut Permeability in Allergic Children N/A
Recruiting NCT05440643 - Peanut Sublingual Immunotherapy (SLIT)-Tablet for Treatment of Peanut Allergy Phase 1
Terminated NCT03849079 - Validation of the HYPONUT Product N/A
Completed NCT02979600 - Clinical and Biological Efficacy of Peanut Oral Immunotherapy N/A
Completed NCT01950533 - The Utility of Food-Specific IgE Measured With the IMMULITE 2000 Assay to Predict Symptomatic Food Allergy
Completed NCT01955109 - Follow-up of the VIPES Study to Evaluate Efficacy and Safety of Viaskin Peanut in Adults and Children Phase 2
Recruiting NCT04415593 - High and Low Dose Oral Peanut Immunotherapy - Comparison of Efficacy and Safety N/A
Active, not recruiting NCT04511494 - Oral Immunotherapy for Young Children With Peanut Allergy - Small Children OIT N/A
Active, not recruiting NCT04887441 - Allergology: Information, Data and Knowledge Organization
Active, not recruiting NCT04881773 - Oral Low Doses Tolerance INduction Study for Peanuts
Completed NCT03682770 - Study in Pediatric Subjects With Peanut Allergy to Evaluate Efficacy and Safety of Dupilumab as Adjunct to AR101 (Peanut Oral Immunotherapy) Phase 2
Terminated NCT03703791 - Real World, Open Label, QOL Assessment of Peanut Immunotherapy AR101 in Children and Adolescents Phase 3
Completed NCT02916446 - Safety Study of Viaskin Peanut to Treat Peanut Allergy Phase 3
Active, not recruiting NCT02402231 - Treatment of Severe Peanut Allergy With Xolair (Omalizumab) and Oral Immunotherapy Phase 2
Recruiting NCT05476497 - Phase I Trial to Evaluate VLP Peanut in Healthy and Peanut Allergic Subjects Phase 1
Completed NCT03648320 - The Grown Up Peanut Immunotherapy Study N/A
Completed NCT03292484 - Longer-term Study of AR101 in Subjects Who Participated in a Prior AR101 Study (ARC008) Phase 3
Completed NCT03852342 - Reactive Doses and Times During Oral Food Challenge to Peanut
Recruiting NCT05138757 - Pinpoint Trial: Prebiotics IN Peanut Oral ImmunoTherapy Phase 1/Phase 2
Completed NCT03352726 - A Study to Assess the Biological Potency of Peanut Allergen Extract in Adolescent and Adult Peanut Allergic Subjects Phase 1